| Line 65: |
Line 65: |
| | | | |
| | ===Laboratory Tests=== | | ===Laboratory Tests=== |
| | + | |
| | + | Coagulation screening tests are unlikely to reveal abnormalities |
| | + | until at least 36 to 72 hours post-exposure. The |
| | + | prothrombin time (PT) generally becomes prolonged |
| | + | first (by 36 to 48 hours), since F-VII, a component of the |
| | + | tissue factor-mediated coagulation pathway, has the |
| | + | shortest half-life (about six hours) and is therefore the |
| | + | first factor to become depleted. The partial thromboplastin |
| | + | time (PTT) and activated clotting time (ACT) are |
| | + | usually prolonged by 48 to 72 hours post-exposure. The |
| | + | thrombin clotting time (TCT), platelet count and buccal |
| | + | mucosal bleeding time (BMBT) (an assessment of |
| | + | platelet function) are usually normal (see table below). |
| | + | The so-called 'proteins induced by vitamin K antagonism' |
| | + | (PIVKA) are acarboxylated proteins formed as a |
| | + | result of anticoagulant rodenticide toxicity. While not |
| | + | normally detected in the circulation, these increase in the |
| | + | plasma of poisoned animals and can be detected using |
| | + | the PIVKA test which is available through some veterinary |
| | + | diagnostic laboratories. PIVKA are usually cleared |
| | + | within 12 hours of administration of vitamin K. Samples |
| | + | for coagulation testing should be collected before initiating |
| | + | vitamin K therapy. |
| | + | Other possible confirmatory tests include quantitation |
| | + | of vitamin K epoxide concentrations and determination |
| | + | of the specific anticoagulant in the blood, liver and/or |
| | + | stomach contents. |
| | + | |
| | ===Pathology=== | | ===Pathology=== |
| | | | |